Compare · MDT vs OM
MDT vs OM
Side-by-side comparison of Medtronic plc. (MDT) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $122.09B, about 1592.0x OM ($76.7M).
- Over the past year, MDT is down 1.2% and OM is down 74.5% - MDT leads by 73.3 points.
- MDT has been more active in the news (29 items in the past 4 weeks vs 2 for OM).
- MDT has more recent analyst coverage (25 ratings vs 13 for OM).
- Company
- Medtronic plc.
- Outset Medical Inc.
- Price
- $94.77-0.74%
- $3.95-1.00%
- Market cap
- $122.09B
- $76.7M
- 1M return
- +2.12%
- +26.81%
- 1Y return
- -1.21%
- -74.53%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 29
- 2
- Recent ratings
- 25
- 13
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest MDT
- SEC Form 4 filed by Medtronic plc.
- SEC Form 4 filed by Medtronic plc.
- Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
- MiniMed Completes Separation from Medtronic
- Medtronic Completes Separation of MiniMed Group, Inc.
- SEC Form 144 filed by Medtronic plc.
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
Latest OM
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- SEC Form 4 filed by Outset Medical Inc.
- SEC Form 8-K filed by Outset Medical Inc.
- Chair and CEO Trigg Leslie sold $15,088 worth of shares (3,437 units at $4.39), decreasing direct ownership by 2% to 194,597 units (SEC Form 4) (tax withholding)
- General Counsel Brottem John L. sold $11,554 worth of shares (2,632 units at $4.39), decreasing direct ownership by 3% to 87,475 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Gaeta Renee sold $19,944 worth of shares (4,543 units at $4.39), decreasing direct ownership by 2% to 180,840 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by Outset Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- SEC Form SCHEDULE 13G filed by Outset Medical Inc.
- SEC Form 10-Q filed by Outset Medical Inc.